Vitrakvi: A New Way to Treat Cancer
A new drug approved by the Food & Drug Administration (FDA) is great news for childhood cancer patients.
The drug – known as larotrectnib, or Vitrakvi – is the first developed to target a key genetic driver of cancer, rather than a specific type of tumor. In this case, the drug targets a gene fusion called NTRK, found in some patients with many different types of cancer.
Dr. Federman, a St. Baldrick’s Scholar from 2009 to 2014, was directly involved in Vitrakvi’s development.